 "Strides Arcolab gets USFDA nod for generic skin disease cream")
The Bangalore-based company has received approval from the US Food and Drug Administration (USFDA) for Imiquimod cream, Strides Arcolab Ltd said in a statement.
"This is the first product approval from Beltapharm, the company's USFDA approved semi-solids facility in Milan, Italy. The product will be marketed directly by Strides in the US market," it added.
Also Read
According to IMS data, the US market for generic Imiquimod cream is around $140 million.
Imiquimod cream is a topical skin cream indicated for the treatment of certain types of actinic keratoses (precancerous skin lesions) on the face or scalp, external genital and perianal warts in patients aged 12 years and more.
Strides shares were trading at Rs 624.75 apiece on the BSE, up 3.46% from its previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%